CUE - Cue Biopharma IND application for cancer candidate CUE-102 accepted by FDA

The U.S. FDA has accepted an Investigational New Drug application from Cue Biopharma (NASDAQ:CUE) for CUE-102, under investigation initially for gastric, pancreatic, ovarian and colon cancers. CUE-102 is designed to treat Wilms' Tumor 1 (WT1)-positive recurrent/metastatic cancers, an onco-fetal protein known to be over-expressed in a number of cancers, according to the company. The acceptance will allow the company to begin a phase 1 dose escalation trial starting at 1 mg/kg. In it Q1 2022 results Tuesday, Cue (CUE) missed on the top and bottom lines.

For further details see:

Cue Biopharma IND application for cancer candidate CUE-102 accepted by FDA